Correvio
Global pharmaceutical company headquartered in London, commercializing specialty, hospital, and rare disease medicines — including originator brands, specialty generics, and biosimilars — across 90+ countries via direct presence in 20+ markets and a 300+ partner network.
- Company typePrivate
- Founded2008
- HeadquartersGeneva, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Correvio does
Correvio (operating data reflects successor entity ADVANZ PHARMA Corp. Limited) is a global pharmaceutical company headquartered in London, United Kingdom, specializing in the commercialization of specialty, hospital, and rare disease medicines. The company markets a portfolio spanning originator brands, specialty generics, and biosimilars across therapeutic areas including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and rare diseases. Recent portfolio additions extend coverage into women's health (Progynova, Cyclo-Progynova), cardiovascular (Ilomedin), and ophthalmology (Eylea biosimilar in development). Commercial sales reach more than 90 countries globally, with a direct commercial presence in over 20 markets — notably key European countries, Canada, and Australia — and a Centre of Excellence in Mumbai, India supporting operations.
The business operates as a partnership-driven commercializer rather than an originator R&D house. It maintains relationships with over 300 partners across production, development, portfolio licensing, and commercialization, and has established co-development arrangements with biosimilar developers such as Alvotech. Marketing authorisations have been secured from the UK MHRA and across the European Economic Area for biosimilars including Gobivaz (golimumab biosimilar), with patent settlements enabling further biosimilar launches. The revenue model is one-time licensing-based pharmaceutical product sales across the global distribution network, with the company positioning itself as the 'partner of choice' for biopharma companies seeking geographic and channel reach for specialty and rare disease assets.
The company is currently engaged in a formal sale process under the UK City Code on Takeovers and Mergers, indicating an active corporate transaction posture. Leadership includes multiple C-suite executives (CEO, CFO, CCO, President) though specific bios are not disclosed in the available data. The firmographic record lists Correvio as a Geneva-based, 2008-founded, delisted (Nasdaq:CORV) entity with 101-250 employees, reflecting its historical interventional cardiology and critical care identity prior to acquisition and rebranding into the broader ADVANZ PHARMA platform.
Correvio firmographics
Firmographics- Name
- Correvio
- Legal name
- ADVANZ PHARMA Corp. Limited
- Website
- https://correvio.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Global pharmaceutical company headquartered in London, commercializing specialty, hospital, and rare disease medicines — including originator brands, specialty generics, and biosimilars — across 90+ countries via direct presence in 20+ markets and a 300+ partner network.
- Ownership category
- akta.pro rank
Correvio industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
Keywords
Where Correvio is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Correvio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Pharmaceutical Product Sales: Revenue generated through commercialization of specialty medicines, specialty generics, biosimilars, and originator brands across global markets.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Correvio product offering
Product offeringCore offering
Correvio is a specialty pharmaceutical company that develops, commercializes, and distributes critical care medicines with a deep focus on interventional cardiology. It also markets a broader portfolio of innovative medicines, specialty generics, originator brands, and biosimilars across therapeutic areas including hepatology, rheumatology, gastroenterology, anti-infectives, endocrinology, CNS, and rare diseases, through direct sales in 20+ countries and a global partner network covering 90+ countries.
Product overview
ADVANZ PHARMA is a global pharmaceutical company that offers a portfolio of innovative medicines, specialty generics, and originator brands. The company specializes in commercialization of specialty, hospital, and rare disease medicines, covering therapeutic areas including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The portfolio also includes biosimilars such as Gobivaz® (Simponi® biosimilar) and an Eylea® biosimilar in development, alongside acquired originator brands like Progynova®, Cyclo-Progynova®, and Ilomedin®.
Differentiator
Problem solved
Functional benefit
Products and services
- Gobivaz
- Eylea Biosimilar
- Progynova
- Cyclo-Progynova
- Ilomedin
Companies that use Correvio
Customer profileSegments3 records
Ideal customer profiles1 record
Correvio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Correvio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AlvotechcoreADVANZ PHARMA and Alvotech have a strategic partnership for biosimilar development and commercialization. They have secured patent settlement for Eylea biosimilar pathway and received marketing approvals for Gobivaz (golimumab biosimilar) across the European Economic Area and from MHRA.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Correvio competitors and assessment
Company assessmentBroad incumbents
- Teva Pharmaceutical Industries: Teva is one of the largest specialty generics manufacturers globally with a substantial biosimilars franchise. It overlaps with ADVANZ in respiratory, CNS, and hospital injectables, plus generic/biosimilar competition.
- Amgen: Amgen is a pioneer biosimilars manufacturer with multiple approved biosimilars in oncology and inflammation. It competes with ADVANZ on the biosimilar opportunity while also being the originator company for several reference products in adjacent categories.
- Merck KGaA (Healthcare): Merck KGaA's healthcare division operates a global specialty pharma and biosimilars business (with Samsung Bioepis partnership). It overlaps with ADVANZ in specialty pharma commercialization and biosimilar strategy across Europe.
- Sandoz: Sandoz is the global biosimilars leader and a generic/specialty pharma major. It competes with ADVANZ in European biosimilar tendering and specialty generics, but operates at far larger scale across more therapy areas.
- Viatris: Viatris (Mylan-Upjohn combination) is a global specialty and generics company with a biosimilars pipeline and established European infrastructure. It competes broadly with ADVANZ in specialty hospital and biosimilar categories.
Direct peers
- Recordati: Recordati is an Italian specialty pharma with focus on rare diseases and hospital/critical care products across Europe. Its therapeutic-area mix and channel overlap make it a close strategic peer.
- Alvotech: Alvotech is ADVANZ's biosimilar co-development partner (Gobivaz, Eylea biosimilar). Both companies develop and commercialize biosimilars to inflammation and ophthalmology reference brands, with overlapping European commercialization infrastructure.
- Hikma Pharmaceuticals: Hikma is a UK-listed specialty generics and injectables company with strong hospital-channel presence in Europe and MENA. It overlaps ADVANZ on hospital medicines, injectables, and specialty distribution.
- Stada Arzneimittel: Stada is a European-focused specialty generics and biosimilars company with broad hospital and specialty distribution. It mirrors ADVANZ's specialty/hospital positioning and pan-European commercialization model.
Emerging players
- Aurobindo Pharma: Aurobindo has rapidly scaled specialty generics, injectables, and biosimilars via subsidiaries (e.g., CuraTeQ). It competes with ADVANZ particularly in hospital injectables and emerging biosimilar categories in Europe.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Correvio social profiles
Digital presenceCorrevio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Correvio leadership team
Management profileNumber of profiles
Profiles5 records
Correvio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Correvio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Correvio
What does Correvio do?
Correvio is a specialty pharmaceutical company that develops, commercializes, and distributes critical care medicines with a deep focus on interventional cardiology. It also markets a broader portfolio of innovative medicines, specialty generics, originator brands, and biosimilars across therapeutic areas including hepatology, rheumatology, gastroenterology, anti-infectives, endocrinology, CNS, and rare diseases, through direct sales in 20+ countries and a global partner network covering 90+ countries.
Is Correvio a public or private company?
Correvio is a private company. It is classified as unknown and is currently operating.
When was Correvio founded?
Correvio was founded in 2008. It employs 101 to 250 people.
Where is Correvio based?
Correvio is headquartered in Geneva, Switzerland, in the Europe region.
How does Correvio make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Correvio's main competitors?
Broad incumbents on record are Teva Pharmaceutical Industries, Amgen, Merck KGaA (Healthcare), Sandoz and Viatris. Direct peers are Recordati, Alvotech, Hikma Pharmaceuticals and Stada Arzneimittel. Aurobindo Pharma is listed as an emerging player.
Does Correvio have an API?
No public API is recorded for Correvio.
What industry is Correvio in?
Correvio's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 42421 and its SIC code is 2834.